Imagine trying to stop a fire by studying a single spark instead of the whole blaze. This team captures individual cancer cells from blood and grows them into tiny 3D balls to see how they behave. By using AI to watch these cells grow and change, they can spot the hidden patterns that tell them if the cancer will spread.
Metastasis causes the vast majority of cancer deaths, but doctors cannot accurately predict which single cells will trigger this spread. Current diagnostics lack the precision to analyze the metabolic and genetic evolution of individual circulating tumour cells.
The 3DSecret-chip for growing 3D cancer spheroids from single cells and a multimodal AI tool for analyzing multi-omics data.
If you are a liquid biopsy developer dealing with the difficulty of predicting cancer spread from blood samples — this project developed the 3DSecret-chip that isolates single circulating tumour cells to predict aggressive behavior. This allows for more precise patient prognosis.
If you are an oncology drug discovery firm dealing with high failure rates in metastasis drugs — this project developed a 3D spheroid model and SERS metabolomics to monitor cell growth kinetics. This provides a more accurate way to test how drugs stop cancer from spreading.
If you are an AI health software provider dealing with a lack of multi-omics training data for cancer — this project developed a multimodal AI tool that integrates genomic, transcriptomic, and metabolomic data. This enables the identification of unknown patterns driving malignancy.
Based on available project data, specific pricing or implementation costs are not provided.
The project uses microfluidics and the 3DSecret-chip for controlled creation of models, but industrial scale-up details are not mentioned in the current data.
Based on available project data, there is no information regarding IP ownership or licensing terms.
The project period is from 2023-01-01 to 2026-12-31, during which a clinical study with 60+ patients is planned.
The system starts with whole blood samples from patients, which is a standard clinical procedure, though the chip analysis happens in a specialized lab setting.
The consortium consists of 6 partners across 4 countries (ES, IT, PT, UK). It is heavily weighted toward research, with 4 research organizations and 1 university, while only 17% of the consortium is industrial (1 SME). This suggests the project is currently focused on high-risk scientific discovery rather than immediate commercial production.
Contact the International Iberian Nanotechnology Laboratory in Portugal.
Contact us to track the clinical study results of the 3DSecret-chip.
